Cipla’s arm inks definitive agreement to sell its entire 48.22% stake in Jiangsu

10 Dec 2014 Evaluate

Cipla’s wholly owned subsidiary - Meditab Holdings, Mauritius, has entered into a definitive agreement to sell its entire 48.22% equity interest in Jiangsu Cdymax Pharmaceuticals Company, China (Jiangsu) to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of $18.5 million. The closing of the transaction is subject to receipt of applicable regulatory approvals in China.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×